Skip to Content

Transcat, Inc. is owned by Royce & Associates LP, which has a $27.33 million position in the company (NASDAQ:TRNS)

Transcat, Inc. is owned by Royce & Associates LP, which has a $27.33 million position in the company (NASDAQ:TRNS)

According to the most recent 13F filing that Royce & Associates LP submitted with the Securities and Exchange Commission, the company’s holdings in Transcat, Inc. (NASDAQ: TRNS) were reduced by 20.3% during the third quarter of this year. The corporation owned a total of 361,044 shares of the company’s stock at the end of the period, having previously sold 91,740 of its shares in the scientific and technical instrument company. The most recent document that Royce & Associates LP has filed with the SEC indicates that the company has an ownership interest in 4.78% of Transcat, which has a current market value of $27,327,000.

Several other large investors have been buying and selling TRNS shares for the past few months. There was a 95.5% increase in Advisor Group Holdings Inc.’s ownership stake in Transcat during the first three months of the year. Advisor Group Holdings Inc. now has a total of 5,107 shares of stock in the scientific and technical instrument company after purchasing an additional 2,495 shares during this period. The value of these shares at the moment is $414,000 in total. The Bank of New York Mellon Corporation increased the amount of Transcat stock owned by 2.8% during the first three months of 2018. The Bank of New York Mellon Corp. now has 35,379 shares of the scientific and technical instruments company’s stock, which has an estimated market value of $2,871,000 after purchasing an additional 948 shares during the period in question. The market value of these shares is estimated to be $2,871,000. The first three months of this year saw US Bancorp DE increase the amount of Transcat stock owned by 137.9%, bringing its total ownership percentage to 100%. Following the acquisition of an additional 200 shares during this period, US Bancorp DE now holds 345 shares of the scientific and technical instruments company’s stock. Each share of this company’s stock is worth $28,000, and the total value of US Bancorp DE’s holdings is $28,000. These shares were gradually obtained throughout the period. During the first three months of 2018, MetLife Investment Management LLC increased the number of shares Transcat owned by 41.3%. After making an additional 1,181 share purchase during the period in question, MetLife Investment Management LLC now has a total of 4,039 shares of the company of the scientific and technical instrument, which gives the holdings a value of $328,000 overall. This brings the total stake that the company owns in the company to 328,000 dollars. And finally, during the first three months of this year, Rhumbline Advisers watched the value of its shares in Transcat rise by 16.1%. Rhumbline Advisers’ holdings in the stock of the company of the scientific and technical instrument have increased to a total of 6,411 shares as a result of the company’s purchase of an additional 890 shares during the most recent quarter. These shares are currently worth $520,000 at the current market price. At this time, institutional investors such as hedge funds and other financial organizations own 83.24% of the company’s shares.

According to news reports related to this topic, on November 3, Director Richard J. Harrison sold 2,509 shares of the company’s stock. This information was made public. It was determined that each share was sold at an average price of $71.97, which resulted in a total sale volume of 180,572.73 dollars. The price at which the shares were sold was determined. The director has recently become the owner of 25,017 shares of the company’s stock, which collectively have a value of approximately $1,800,473.49. You will be taken to a legal file submitted to the SEC if you click on the link we have provided, where you will find additional information regarding the sale. Within the company, insiders hold 4.8 percent of the total number of outstanding shares.

Recently, numerous analyst reports have discussed TRNS as a topic of discussion. On Wednesday, October 12, coverage on StockNews.com was increased to include Transcat after the company had been added the day before. They recommended that shareholders “hold” their shares of the company. HC Wainwright raised their price objective on shares of Transcat from $85.00 to $88.00 and gave the stock a “buy” rating in a research report published on November 2. While one equity research expert has suggested that investors maintain their current stock holdings, the other four have rated the stock as a buy and encouraged investors to do so. The company has been given a “Moderate Buy” rating, the average recommendation from analysts at Bloomberg. The price target of $87.25 has received the most support from most analysts.

A share of TRNS stock started the trading day on Thursday at an opening price of $82.05 per share. The company’s beta value is 0.77, and its price-to-earnings ratio stands at 62.16. The company currently has a market capitalization of $620.13 million and a price of $82.05 per share. The company’s beta value is 0.77, and its price-to-earnings ratio stands at 62.16. The company currently has a market capitalization of $620.13 million. The company has experienced a moving average of $73.19 over the previous 200 days; the moving average for the previous 50 days is $76.20. The values come in at 1.84 for the quick ratio, 2.52 for the current ratio, and 0.53 for the debt-to-equity ratio, respectively. During the previous year, the price of a share of Transcat, Inc. fluctuated between $50.32 and $95.79 across its trading range.

On October 31, a Monday, the most recent quarterly earnings report for Transcat (NASDAQ: TRNS) was made public for the first time. The manufacturer of scientific and technical equipment reported earnings per share for the quarter of $0.31, which was $0.07 less than the consensus estimate of $0.38 from market analysts. The company reported sales of $56.44 million for the quarter, which is significantly higher than the general projection of $54.90 million made by market analysts. Transcat had a return on equity of 12.76%, and the net margin for the company was 4.64%. According to the projections made by experts in equity research, each share of common stock owned by Transcat, Inc., will bring in a profit of $1.39 during the current fiscal year.

Transcat, Inc. provides laboratory instrument calibration services in various countries, including the United States of America, Canada, and other locations. Distribution and service are the two main facets of this company’s business operations that make it up. Service is the division that provides services such as calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other associated services. These can all be obtained through the service division.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *